On February 17, 2021 EMERCell, a biotechnology company developing immunotherapies and cell-based therapies for oncology targets through to pharmaceutical development, reported the signature of a strategic partnership with Onward Therapeutics (Press release, EMERCell, FEB 17, 2021, View Source [SID1234575226]). The significant investment, of a confidential amount, will be made in three instalments that will allow EMERCell to reach the first human clinical trials.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are delighted to partner with Onward Therapeutics, whose teams have recognized expertise in the development of new drugs in oncology and with whom we have strong synergies. Their participation is a recognition of our expertise and will allow us to accelerate our development," said Patrick Henno, founder and Chairman of EMERCell.
"We are pleased to collaborate with EMERCell to scale up their patented process of activation and amplification of the allogeneic NK cells for clinical development," said Dr. C. Grace Yeh, Chairman and CEO of Onward. "Accessing to the highly activated NK cells allows Onward to explore their potentials for improved efficacy in the immunotherapy for cancer patients."
During the last few years, EMERCell, with the support of the Italian company Bioline diagnostici, has developed and patented, in partnership with the University Hospital of Montpellier, the University of Montpellier and Inserm, a process for the production of a therapeutic tool composed of NK cells. EMERCell is now focusing on the development of its first product, NK-001, a new innovative therapy drug (ATMP) for the treatment of cancer.